期刊文献+

晚期前列腺癌的治疗及其并发症的处理(附71例报告) 被引量:4

下载PDF
导出
摘要 目的探讨晚期前列腺癌及并发症的处理以期提高其治疗效果。方法71例晚期前列腺癌患者接受雄激素全阻断治疗(MAB),对骨痛、膀胱流出道梗阻、输尿管梗阻、膀胱出血及直肠梗阻等并发症分别予止痛剂、二膦酸盐、氯化锶(89Sr)、经尿道前列腺电切或膀胱造瘘、双J管留置、膀胱镜电灼止血、放射性粒子(125I)植入等治疗。结果死亡17例,3例死于肝转移,12例死于多器官转移的呼吸循环衰竭,2例死于心、脑血管疾病。骨转移48例,出现骨痛39例,予止痛剂治疗,28例缓解5-22个月;未能缓解者,予二膦酸盐治疗5例,4例缓解4-10个月;89Sr治疗6例,5例缓解2-5个月。尿潴留21例,13例行耻骨上膀胱造瘘术,8例行经尿道前列腺电切术(TURP),解除梗阻12个月以上。输尿管梗阻3例,留置双J管,随访5-12个月血尿素氮及肌酐均无明显增高。突发膀胱出血5例,予膀胱镜电灼止血,术后3个月血尿反复。浸润直肠1例,1251植入3d后盆底疼痛,直肠出血,梗阻症状渐消。结论对晚期前列腺癌及并发症,采用及时、有效的处理,可显著改善症状,提高生活质量。
出处 《海南医学》 CAS 2009年第9期47-48,43,共3页 Hainan Medical Journal
  • 相关文献

参考文献6

  • 1鲍镇美.晚期前列腺癌的治疗新动向[J].中华泌尿外科杂志,2002,23(2):69-71. 被引量:47
  • 2Prostate Cancer trialists Collaborative Grop. Maximum androgen blockade in advanced Prostate Cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients[ J]. Lancet, 1995, 346 ( 8970 ) : 265 - 269.
  • 3Labile F, Dupont A, Giguere M, et al. Advantages of combination therapy in previously untreated and treated patients with advanced Prostatic Cancer[J]. J Steroid Biochem, 1986,25 (SB) : 877 - 883.
  • 4Edwards J, Krishna NS,Grigor KM, et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer[ J]. Br J Cancer, 2003, 89 (3) : 552 - 556.
  • 5白文俊,王晓峰,朱积川,侯树坤.晚期前列腺癌患者骨痛的处理(附八例报告)[J].中华泌尿外科杂志,2002,23(2):80-82. 被引量:8
  • 6Garnick MB. Prostate Cancer: screening, diagnosis and management [ J ]. Ann Intern Med, 1993, 118 (10) : 804 - 818.

二级参考文献12

  • 1ShenfeldO,SchellhammerPF.Androgendeprivationtherapy[].Pro staticdisease.2000
  • 2Chawnshang Chang.A dominant negative mutant of androgen receptor coactivator ARA54, suppresses androgen receptor transactivation in prostate cancer cell[].J Urol th AUA meeting #.
  • 3Prehen RT.On the prevention and therapy of prostate cancer by androgen administration[].Cancer Research.1999
  • 4Umekita Y,Kolontis JM,Shutsung L.Human prostate tumor growth in athymic mice-inhibition by androgen and stimulation by finasteride[].Proceedings of the National Academy of Sciences of the United States of America.1996
  • 5Hai Yen E,Shiming Chang,Chung WK,et al.Androgen-repressed phenotype in human prostate cancer[].Proceedings of the National Academy of Sciences of the United States of America.1996
  • 6Din Lii Lin,Zhi Yao,Keller ET.Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression[].Clinical Cancer Research.2001
  • 7Okamoto M,Lee C,Oyasu R.Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro[].Cancer Research.1996
  • 8Hobisch A,Klocker H,Culig Z,et al.Interleukin-6 regulates prostatespecific protein expression in prostate carcinoma cells by activation of the androgen receptor[].Cancer Research.1998
  • 9Chen T,Wang LH,Farrar WL.Interleukin 6 activates androgen receptor-mediated gene expression through a transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells[].Cancer Research.2000
  • 10Peter C,Smith,Keller ET.Anti-interleukin-6 monoclonal antibo dy inhibits prostate cancer growth in vivo[].nd meeting of AACR New Orleans LA.2001

共引文献50

同被引文献65

  • 1白涛,张杰.前列腺癌免疫治疗新进展——sipuleucel-T[J].世界临床药物,2009,30(11):646-649. 被引量:3
  • 2陈龙.20例前列腺癌的临床分析[J].海南医学,2005,16(4):32-33. 被引量:2
  • 3陆嘉德.转移性前列腺癌的内分泌治疗[J].中国癌症杂志,2007,17(3):205-212. 被引量:3
  • 4Deliveliotis C, Varkarkis J, Albanis S, et al. Biopsies of the transi- tional zone of the prostate. Should it be done on a routine basis, when and why? J Urol,2002,68(2) :113 -117.
  • 5Sakai I, Harada K, Kurahashi T, et al. Analysis of differences in clinicopathological features between prostate cancers the transition and peripheral zones. Int J Urol,2006,13(4) :368 -372.
  • 6Peyromaure M, Bavery V, Boecon - gibod L. The management of stress urinary incontinence after radical prostatectomy. BJU Int. 2002,90(2) :155.
  • 7Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cancer J Clin,2011,61 (2) :69-90.
  • 8Hiroshi Miyamoto, Edward M Messing, Chawnshang Chang, et al. An- drogen Deprivation Therapy for Prostate Cancer: Current Status and Future Prospects [ J ]. The Prostate,2004,61 (4) :332-353.
  • 9Seidenfeld J, Samson D J, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer:a systematic review And meta-analysis [ J ]. Ann Intern Med,2000,132 (7) :566-577.
  • 10Gommersall LM, Hayne D, Shergill IS, et al. Luteinising hormone re- leasing hormone analogues in the treatment of prostate cancer [ J ]. Expert opinion on pharmacotherapy ,2002,3 ( 12 ) : 1685-1692.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部